Felcorekibart for chronic obstructive pulmonary disease (COPD)
Part of Lungs & breathing clinical trials.
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 40 to 80 years old
- Have moderate to severe COPD with frequent flare-ups
- Have high blood levels of eosinophils, a type of white blood cell
- Currently use inhaled COPD treatments, like triple therapy or dual inhalers, if appropriate
- Be a current or former smoker
- Not have asthma or other significant lung disease
- Not have had a recent heart attack, stroke, or heart failure
- Not have used oxygen therapy for more than 16 hours a day
- Not have had cancer in the last 5 years (except for treated skin cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This study tests a new medication called felcorekibart for people with chronic sinusitis and nasal polyps. It may help reduce symptoms like congestion and loss of smell.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This trial tests an investigational drug called Rademikibart for people having a severe asthma or COPD flare-up that needs emergency care and steroids. The study aims to see if the drug can help control the flare-up faster and reduce the need for more treatment.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.